Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down.
Over its 25-year history, Alexandria Real Estate Equities Inc. has built a life sciences real estate empire by anticipating the growth and infrastructure needs of the biotech and tech sectors, buying up property and developing office and lab spaces in hubs such as Boston, San Francisco, San Diego, Seattle and Research Triangle Park in North Carolina.
The strategy has produced an S&P 500 company with a market cap of more than $16 billion and total 2018 revenues of $1.3 billion.
The firm’s history of making venture investments in biotech dates back to at least 2001.
In the last 18 months Alexandria has ramped up its pace of dealmaking to become the most active venture investor in biotech.
But in the last 18 months